{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:11:29Z","timestamp":1789236689746,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejps.2026.107563","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:50:42Z","timestamp":1779346242000},"page":"107563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Tofersen in SOD1-associated amyotrophic lateral sclerosis: From molecular mechanisms to regulatory milestones"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2669-7006","authenticated-orcid":false,"given":"Antonio J.","family":"Braza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8376-1088","authenticated-orcid":false,"given":"Montserrat","family":"Vi\u00f1as-Bastart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7403-3804","authenticated-orcid":false,"given":"Maria","family":"Sureda-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4458-2711","authenticated-orcid":false,"given":"Beliu","family":"Garc\u00eda-Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6730-7348","authenticated-orcid":false,"given":"Josep M.","family":"Guiu-Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3193-6285","authenticated-orcid":false,"given":"Pilar","family":"Modamio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejps.2026.107563_bib0002","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41576-023-00592-y","article-title":"Amyotrophic lateral sclerosis: translating genetic discoveries into therapies","volume":"24","author":"Ak\u00e7imen","year":"2023","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"10.1016\/j.ejps.2026.107563_bib0003","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrneurol.2016.182","article-title":"Gene discovery in amyotrophic lateral sclerosis: implications for clinical management","volume":"13","author":"Al-Chalabi","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.ejps.2026.107563_bib0004","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/jnnp-2016-313521","article-title":"Defining SOD1 ALS natural history to guide therapeutic clinical trial design","volume":"88","author":"Bali","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.ejps.2026.107563_bib0005","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","article-title":"Design of a randomized, placebo-controlled, phase 3 trial of Tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study","volume":"19","author":"Benatar","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"16","key":"10.1016\/j.ejps.2026.107563_bib0006","article-title":"Phenotypic characterization of ALS-causing SOD1 mutations affecting polypeptide length","volume":"2025","author":"Berdy\u0144ski","year":"2025","journal-title":"Hum. Mutat."},{"issue":"2","key":"10.1016\/j.ejps.2026.107563_bib0007","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Brown","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ejps.2026.107563_bib0008","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000516752","article-title":"Estimated prevalence and incidence of amyotrophic lateral sclerosis and SOD1 and C9orf72 genetic variants","volume":"55","author":"Brown","year":"2021","journal-title":"Neuroepidemiology"},{"issue":"1\u20132","key":"10.1016\/j.ejps.2026.107563_bib0009","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (Phase III)","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ejps.2026.107563_bib0010","article-title":"Tofersen: treatment & management","author":"Cerillo","year":"2023","journal-title":"NCBI Bookshelf"},{"issue":"5","key":"10.1016\/j.ejps.2026.107563_bib0014","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/17582024.2024.2402216","article-title":"Tofersen for SOD1 ALS","volume":"14","author":"Everett","year":"2024","journal-title":"Neurodegener. Dis. Manage"},{"issue":"3\u20134","key":"10.1016\/j.ejps.2026.107563_bib0016","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/21678421.2024.2320880","article-title":"The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials","volume":"25","author":"Genge","year":"2024","journal-title":"Amyotroph. Lateral. Scler. FrontotempOral Degener."},{"key":"10.1016\/j.ejps.2026.107563_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102972","article-title":"ALS-linked SOD1 mutations impair mitochondrial-derived vesicle formation and accelerate aging","volume":"69","author":"Guo","year":"2024","journal-title":"Redox. Biol."},{"issue":"5","key":"10.1016\/j.ejps.2026.107563_bib0018","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s10072-025-07994-2","article-title":"Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"46","author":"Hamad","year":"2025","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2026.107563_bib0019","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40035-024-00416-x","article-title":"Variability in SOD1-associated amyotrophic lateral sclerosis: geographic patterns, clinical heterogeneity, molecular alterations, and therapeutic implications","volume":"13","author":"Huang","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.ejps.2026.107563_bib0020","series-title":"Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data","year":"2018"},{"issue":"11","key":"10.1016\/j.ejps.2026.107563_bib0021","first-page":"37","article-title":"Tofersen gains accelerated approval for ALS","volume":"48","author":"Lisi","year":"2023","journal-title":"US. Pharm."},{"issue":"1","key":"10.1016\/j.ejps.2026.107563_bib0022","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4103\/NRR.NRR-D-23-01904","article-title":"Multifaceted superoxide dismutase 1 expression in amyotrophic lateral sclerosis patients: a rare occurrence?","volume":"20","author":"Martinelli","year":"2025","journal-title":"Neural Regener. Res."},{"issue":"10","key":"10.1016\/j.ejps.2026.107563_bib0023","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/ene.14393","article-title":"Amyotrophic lateral sclerosis: a clinical review","volume":"27","author":"Masrori","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.ejps.2026.107563_bib0024","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI99081","article-title":"Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models","volume":"128","author":"McCampbell","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.ejps.2026.107563_bib0025","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s40263-025-01204-5","article-title":"Tofersen: a review in amyotrophic lateral sclerosis associated with SOD1 mutations","volume":"39","author":"McGuigan","year":"2025","journal-title":"CNS. Drugs"},{"issue":"3","key":"10.1016\/j.ejps.2026.107563_bib0027","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mus.28182","article-title":"Clinical and patient-reported outcomes and neurofilament response during tofersen treatment in SOD1-related ALS-A multicenter observational study over 18\u2009months","volume":"70","author":"Meyer","year":"2024","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.ejps.2026.107563_bib0028","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ejps.2026.107563_bib0029","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ejps.2026.107563_bib0030","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3390\/genes15101342","article-title":"Recent progress of antisense oligonucleotide therapy for superoxide-dismutase-1-mutated amyotrophic lateral sclerosis: focus on Tofersen","volume":"15","author":"Moriyama","year":"2024","journal-title":"Genes. (Basel)"},{"issue":"11","key":"10.1016\/j.ejps.2026.107563_bib0031","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3390\/cells13110888","article-title":"Updates on disease mechanisms and therapeutics for amyotrophic lateral sclerosis","volume":"13","author":"Nguyen","year":"2024","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.ejps.2026.107563_bib0035","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/14737175.2024.2355983","article-title":"Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis","volume":"24","author":"Oliveira-Santos","year":"2024","journal-title":"Expert. Rev. NeurOther"},{"key":"10.1016\/j.ejps.2026.107563_bib0036","article-title":"Tofersen: safety and adverse events","author":"Qalsody","year":"2025","journal-title":"Warnings Precaut."},{"issue":"1","key":"10.1016\/j.ejps.2026.107563_bib0037","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-94984-1","article-title":"Neurodegenerative and neuroinflammatory changes in SOD1-ALS patients receiving tofersen","volume":"15","author":"Simonini","year":"2025","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ejps.2026.107563_bib0039","article-title":"Excitotoxicity and ALS: new therapy targets an old mechanism","volume":"5","author":"Smith","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"2","key":"10.1016\/j.ejps.2026.107563_bib0040","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/acn3.52264","article-title":"Tofersen treatment leads to sustained stabilization of disease in SOD1 ALS in a \"real-world\" setting","volume":"12","author":"Smith","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ejps.2026.107563_bib0041","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fncel.2015.00336","article-title":"SOD1 misplacing and mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis","volume":"9","author":"Tafuri","year":"2015","journal-title":"Front. Cell Neurosci."},{"key":"10.1016\/j.ejps.2026.107563_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1383453","article-title":"Protein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS","volume":"11","author":"Tsekrekou","year":"2024","journal-title":"Front. Mol. Biosci."},{"issue":"9","key":"10.1016\/j.ejps.2026.107563_bib0043","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/ene.15661","article-title":"Characterizing SOD1 mutations in Spain. the impact of genotype, age, and sex in the natural history of the disease","volume":"30","author":"V\u00e1zquez-Costa","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejps.2026.107563_bib0044","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2667-0496(24)00234-5","article-title":"Epidemiolog\u00eda de la ELA en Catalu\u00f1a (2015\u20112020)","volume":"4","author":"Vidal Notari","year":"2024","journal-title":"Neurol. Perspect."},{"key":"10.1016\/j.ejps.2026.107563_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102495","article-title":"Effects of tofersen treatment in patients with SOD1-ALS in a \"real-world\" setting - a 12-month multicenter cohort study from the German early access program","volume":"69","author":"Wiesenfarth","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.ejps.2026.107563_bib0046","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/s42003-021-02862-z","article-title":"Novel chemical inhibitor against SOD1 misfolding and aggregation protects neuron-loss and ameliorates disease symptoms in ALS mouse model","volume":"4","author":"Woo","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejps.2026.107563_bib0047","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pneurobio.2016.05.004","article-title":"ALS: a bucket of genes, environment, metabolism and unknown ingredients","volume":"142","author":"Zufir\u00eda","year":"2016","journal-title":"Prog. Neurobiol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:14:37Z","timestamp":1781752477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726001375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"alternative-id":["S0928098726001375"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107563","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tofersen in SOD1-associated amyotrophic lateral sclerosis: From molecular mechanisms to regulatory milestones","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107563"}}